These responses are correlated with a better or worse prognosis for HCC patients, respectively.9 The small molecule kinase inhibitor galunisertib selectively blocks TGF-β receptor 1 (TGF-βR1), thereby inhibiting the induction of the canonical Smad-2 signaling pathway. This evidence concerns the gene SMAD2 and hepatocellular carcinoma.